HomeCompareFIXX vs KMB

FIXX vs KMB: Dividend Comparison 2026

FIXX yields 213.97% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FIXX wins by $177.38M in total portfolio value
10 years
FIXX
FIXX
● Live price
213.97%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.43M
Annual income
$92,441,271.48
Full FIXX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — FIXX vs KMB

📍 FIXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIXXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIXX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FIXX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIXX
Annual income on $10K today (after 15% tax)
$18,187.65/yr
After 10yr DRIP, annual income (after tax)
$78,575,080.76/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, FIXX beats the other by $78,570,641.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIXX + KMB for your $10,000?

FIXX: 50%KMB: 50%
100% KMB50/50100% FIXX
Portfolio after 10yr
$88.74M
Annual income
$46,223,246.91/yr
Blended yield
52.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

FIXX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$2.70
+188.9% upside vs current
Range: $2.70 — $2.70
Altman Z
-2.8
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIXX buys
0
KMB buys
0
No recent congressional trades found for FIXX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIXXKMB
Forward yield213.97%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$177.43M$45.9K
Annual income after 10y$92,441,271.48$5,222.34
Total dividends collected$167.81M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$2.70$123.00

Year-by-year: FIXX vs KMB ($10,000, DRIP)

YearFIXX PortfolioFIXX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$32,097$21,397.24$11,314$614.45+$20.8KFIXX
2$98,530$64,186.20$12,867$760.19+$85.7KFIXX
3$289,572$184,144.93$14,713$945.27+$274.9KFIXX
4$815,624$505,782.06$16,924$1,181.90+$798.7KFIXX
5$2,204,131$1,331,413.21$19,596$1,486.64+$2.18MFIXX
6$5,721,029$3,362,608.71$22,850$1,882.16+$5.70MFIXX
7$14,278,479$8,156,977.31$26,849$2,399.80+$14.25MFIXX
8$34,304,224$19,026,251.97$31,812$3,083.36+$34.27MFIXX
9$79,425,902$42,720,382.43$38,033$3,994.72+$79.39MFIXX
10$177,426,987$92,441,271.48$45,918$5,222.34+$177.38MFIXX

FIXX vs KMB: Complete Analysis 2026

FIXXStock

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Full FIXX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this FIXX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIXX vs SCHDFIXX vs JEPIFIXX vs OFIXX vs KOFIXX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.